Jak2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Protein Name** | Janus Kinase 2 (JAK2) |
| **Gene Symbol** | [JAK2](/genes/jak2) |
| **UniProt ID** | [O60674](https://www.uniprot.org/uniprot/O60674) |
| **Molecular Weight** | ~130 kDa |
| **Subcellular Localization** | Cytoplasm, associated with membranes |
| **Protein Family** | Janus kinase family |
| **PDB Structure** | [4IVB](https://www.ebi.ac.uk/pdbe/entry/pdb/4IVB), [5Y6J](https://www.ebi.ac.uk/pdbe/entry/pdb/5Y6J) |
Janus Kinase 2 (JAK2) is a cytoplasmic tyrosine kinase essential for signaling by cytokines and growth factors. It plays a central role in immune regulation, hematopoiesis, and cellular responses to stress.
JAK2 contains multiple functional domains:
- FERM domain (JH7-JH5): Binds cytokine receptor cytoplasmic domains
- SH2-like domain (JH4-JH3): Regulatory
- Pseudokinase domain (JH2): Autoinhibition, V617F mutation site
- Kinase domain (JH1): Catalytic tyrosine kinase activity
The V617F mutation in JH2 domain causes constitutive activation.
- Associates with cytokine receptors (not receptor tyrosine kinases)
- Transphosphorylates and activates upon ligand binding
- Phosphorylates STAT transcription factors
- Initiates gene expression programs
- Interleukin-6 family cytokines
- Interferon-α/β
- Erythropoietin (EPO)
- Thrombopoietin (TPO)
- Granulocyte colony-stimulating factor (G-CSF)
- JAK2/STAT3 hyperactivated in AD brain
- Mediates inflammatory responses to Aβ plaques
- Contributes to microglial activation
- Modulates neuronal survival
- Elevated in substantia nigra pars compacta
- Contributes to neuroinflammation
- Involved in glial responses
- Dopaminergic neuron vulnerability
- Dysregulated JAK2/STAT3 in ALS models
- Activated in motor neurons and glia
- Contributes to inflammation
- Central to CNS autoimmune inflammation
- JAK inhibitors show promise in trials
| Drug |
Specificity |
Clinical Use |
| Ruxolitinib |
JAK1/JAK2 |
Myelofibrosis, GVHD |
| Tofacitinib |
JAK1/JAK2/JAK3 |
Rheumatoid arthritis |
| Baricitinib |
JAK1/JAK2 |
Rheumatoid arthritis |
| Fedratinib |
JAK2 |
Myelofibrosis |
- Ben H, et al. (2019). "JAK2 in neuroinflammation and AD." J Neuroinflammation. PMID:30654698
- Liu J, et al. (2018). "JAK2/STAT3 neuroprotection." Movement Disorders. PMID:29578456
The study of Jak2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- JAK2-STAT3 signaling in neuroinflammation (2010)
- Role of JAK2 in Alzheimer's disease (2015)
- JAK2 inhibition protects against neuronal death (2014)
- Cytokine-mediated JAK2-STAT3 activation in PD (2016)
- JAK inhibitors as therapeutic agents for neurodegeneration (2019)
- Microglial JAK2-STAT3 in AD pathogenesis (2020)